Skip to content

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

PUBLICATIONS

NASH, PUBLICATIONS

Denifanstat, a Fatty Acid Synthase Inhibitor, Increased Circulating Polyunsaturated Triglycerides and Decreased LDL-Cholesterol in MASH Patients with Advanced Fibrosis in a Post-Hoc Analysis of FASCINATE-2 Study

By Graviton / 02/2025

Keystone Symposia

NASH, PUBLICATIONS

FASN inhibitor

By Graviton / 01/2025

MASH TAG

NASH, PUBLICATIONS

Denifanstat showed anti-fibrotic effect both on conventional and digital pathology in a metabolic dysfunction-associated steatohepatitis (MASH) Phase 2b trial (FASCINATE-2)

By Graviton / 01/2025

MASH TAG

NASH, PUBLICATIONS

AI-Based Digital Pathology Shows that Denifanstat Improves Multiple Parameters of Fibrosis and Reduces Progression to Cirrhosis in MASH patients with F2/F3

By Graviton / 11/2024

AASLD The Liver Meeting

NASH, PUBLICATIONS

Denifanstat significantly improves liver fibrosis in difficult-to-treat MASH patients – Results from conventional and AI-based pathology from the phase 2b FASCINATE-2, a 52-week randomized, double-blind, placebo-controlled trial

By Graviton / 11/2024

AASLD The Liver Meeting

NASH, PUBLICATIONS

Fatty acid synthase (FASN) inhibitor reduces atherosclerosis development in diet-induced dyslipidaemia LDL receptor knockout mice with MASH

By Graviton / 11/2024

AASLD The Liver Meeting

NASH, PUBLICATIONS

Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial

By Graviton / 10/2024

The Lancet Gastroenterology & Hepatology

NASH, Oncology, PUBLICATIONS, Virology

Demonstrating denifanstat’s differentiated approach in MASH with mechanistic and clinical data showing direct anti-fibrotic activity

By Graviton / 09/2024

8th Annual MASH Drug Development Summit

NASH, PUBLICATIONS

Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist resmetirom shows synergistic improvement of NAFLD activity score (NAS) within 6-weeks in diet-induced obese mice with biopsy-confirmed MASH

By charlie maddox / 06/2024

EASL International Liver Congress

NASH, PUBLICATIONS

Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of MASH and cardiovascular health in LDL receptor knockout MASH mice

By charlie maddox / 06/2024

EASL International Liver Congress

Post pagination

← Previous 1 2 3 … 10 Next →

Site map

About
Science
Investors
Programs
Contact

About
Science
Investors
Programs
Contact

Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2025 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

Scroll to Top